Drug profile · INN
aumolertinib
AUMSEQA
aumolertinib (AUMSEQA) is a epidermal growth factor receptor erbb1 inhibitor.
EMA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EB
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — aumolertinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
aumolertinib (AUMSEQA) is a epidermal growth factor receptor erbb1 inhibitor.
Key facts
INN aumolertinib
Brand AUMSEQA
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EB
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is aumolertinib?
aumolertinib (AUMSEQA) is a epidermal growth factor receptor erbb1 inhibitor.
What is the brand name for aumolertinib?
AUMSEQA is a marketed brand name for aumolertinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.